spacer
home > epc > autumn 2002 > in mergers - not the only way to grow
PUBLICATIONS
European Pharmaceutical Contractor

In Mergers - Not the Only Way to Grow

Contrary to the opinion of many industry analysts, the pharmaceutical industry is likely to see a slowdown in major merger and acquisition (M&A) activity in the near future. For growth, companies should look to other opportunities, such as more ambitious developments in the large, challenging markets of Japan, China and Brazil.

The Need for Action

The pharmaceutical industry has performed extremely well for many years, with high rates of profit and sales growth. The sector is very highly rated by investors and stock analysts. However, pressures which impact on revenues and profits are steadily growing for global pharmaceutical companies. For example, companies in the USA are suffering from problems of escalating sales and marketing costs. At the same time, they are facing product price pressures by insurers trying to contain private sector health costs. Europe is beset by R&D productivity problems, growing generic competition and the need to contain health costs in the public sector
(seeTable 1).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By John Morris, Head of KPMG's European Pharmaceutical Practic

John Morris is Head of KPMG's European Pharmaceutical Practice. Having graduated in chemistry, he joined KPMG and became a qualified Chartered Accountant, focusing on the chemicals and pharmaceuticals sectors.

John has been heavily involved in the international activities of the chemical and pharmaceutical industries, focusing mainly on issues related to mergers, acquisitions and divestments as the industries restructure and companies strive to improve performance.

spacer
John Morris
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Launches Partner Program to Team with Clinical Research Organizations (CROs) Committed to Improving Clinical Trials with Patient-Centric Technology

PHILADELPHIA – August 12, 2019: Signant Health (signanthealth.com), a leading provider of technology for clinical research, today launches the Signant Health Partner Program, a significant investment the company is making to enable clinical research organizations (CROs) to better serve sponsors in the areas of Patient Data, Patient Experience, Clinical Supplies, and Endpoint Quality Solutions. By becoming a Signant Partner, CROs will benefit from new commercial and operational advantages that only come with membership.
More info >>

White Papers

High Potency Drugs – from Molecule to Market

PCI Pharma Services

PCI Pharma Services has invested in state-of-the-art containment equipment and created a ‘Potent Passport’ philosophy to identify the specific handling requirements for any Highly Potent Active Pharmaceutical Ingredients (HPAPI) project. Backed by 30 years’ experience of managing potent molecules, PCI Pharma Services is the logical choice when selecting an outsourcing partner.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India forhigh quality, low   cost pharma solutions, CPhI & P-MEC Indiais the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India’s pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement